Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Harris

Internal Medicine Clarkston, MI Medical Doctor

NPI 1154314029 CMS profile 142686

5900 Waldon Rd Ste D, Clarkston, MI 48346

Open in the dashboard

General payments

$8,591

526 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Harris of Clarkston, MI is reported in the CMS Open Payments database as having received $8,591 across 526 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $250 13
2024 General $1,995 107
2023 General $2,017 98
2022 General $1,261 69
2021 General $862 57
2020 General $180 12
2019 General $2,027 170

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Harris
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Harris were reported at $250. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Harris Internal Medicine median Middle half National median
2019 $2,027 $159 $48–$570 $163
2020 $180 $119 $33–$402 $114
2021 $862 $135 $37–$521 $132
2022 $1,261 $141 $42–$496 $149
2023 $2,017 $149 $45–$519 $160
2024 $1,995 $154 $47–$537 $164
2025 $250 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,428 63 payments
  2. AstraZeneca Pharmaceuticals LP $1,046 60 payments
  3. Novo Nordisk Inc $773 61 payments
  4. Amgen Inc. $651 34 payments
  5. Lilly USA, LLC $551 34 payments
  6. AbbVie, Inc. $402 35 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $389 27 payments
  8. Pfizer Inc. $380 39 payments
  9. Novartis Pharmaceuticals Corporation $267 15 payments
  10. Otsuka America Pharmaceutical, Inc. $239 11 payments
  11. Other $2,464 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,585 525 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $776 43 payments
  2. Ozempic $604 51 payments
  3. TRELEGY ELLIPTA $576 42 payments
  4. RYBELSUS $530 46 payments
  5. AREXVY $516 9 payments
  6. Repatha $387 20 payments
  7. BREZTRI $314 8 payments
  8. Prolia $309 17 payments
  9. TRULICITY $303 20 payments
  10. EVENITY $264 14 payments
  11. Other $7,081 468 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 173 drugs

Part D claims

14,476

Median for Internal Medicine: 777

Drug cost

$1,643,125

Median for Internal Medicine: $73,373

Branded share of claims

27.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 220 $219,400
Eliquis Apixaban Brand 197 $186,303
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 220 $170,385
Mounjaro Tirzepatide Brand 74 $122,019
Farxiga Dapagliflozin Propanediol Brand 115 $96,557
Ozempic Semaglutide Brand 58 $82,048
Trulicity Dulaglutide Brand 41 $68,529
Januvia Sitagliptin Phosphate Brand 56 $48,976
Xarelto Rivaroxaban Brand 34 $42,660
Prolia Denosumab Brand 23 $38,889

The 10 drugs with the highest cost, of 173 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$96,355

Of which drugs: $8,910

Medicare patients

253

Average age 73

Services billed

12,152

132 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 36%
Chronic kidney disease 31%
Diabetes 24%
COPD 23%
Ischemic heart disease 19%
Atrial fibrillation 15%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 75 77 $6,261
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 1,600 $164
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 46 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $190
$190 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $142
$142 220 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $140
$140 36 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $134
$134 — —
REXULTI
  • Lundbeck LLC $77
  • Otsuka America Pharmaceutical, Inc. $53
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record